Want to see IN:PPLPHARMA full AI Analyst Report?
PPLPHARMA Stock Chart & Stats
₹192.65
-₹4.80(-1.92%)
At close: 4:00 PM EST
₹192.65
-₹4.80(-1.92%)
Day’s Range― - ―
52-Week Range₹132.50 - ₹217.75
Previous CloseN/A
Volume1.66M
Average Volume (3M)264.14K
Market Cap
₹239.04B
Enterprise Value₹261.25B
Total Cash (Recent Filing)₹13.55B
Total Debt (Recent Filing)₹56.75B
Price to Earnings (P/E)―
Beta0.77
Next Earnings
Aug 05, 2026EPS Estimate
-0.66Next Dividend Ex-DateN/A
Dividend Yield0.08%
Share Statistics
EPS (TTM)-2.47
Shares Outstanding1,331,348,100
10 Day Avg. Volume501,791
30 Day Avg. Volume264,138
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)2.22
Price to Sales (P/S)2.04
P/FCF Ratio35.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.45
Revenue Forecast (FY)₹100.54B
Bulls Say, Bears Say
Bulls Say
Diversified Business ModelPiramal Pharma's three distinct lines (CDMO, complex hospital generics, OTC consumer healthcare) create durable revenue diversity. CDMO contracts deliver multi-year demand, hospital generics provide institutional volume stability, and OTC adds retail cash flow, reducing single-market dependency.
Multi-year Revenue ScalingSustained revenue expansion to ~₹88.7B demonstrates successful commercial scaling and market penetration. Larger top line supports higher plant utilization, bargaining power with suppliers/customers, and the ability to invest in capacity and specialized capabilities that underpin long-term CDMO and complex-generic margins.
Improved Cash GenerationA shift to materially stronger operating cash flow and positive FCF (~₹5.1B) indicates better working-capital management and operational leverage. This strengthens internal funding for capex, supports contractual CDMO investments, and offers more capacity to reduce leverage or fund strategic initiatives over the medium term.
Bears Say
Profitability VolatilityRecurring swings to net losses undermine the durability of earnings quality. Even with revenue growth, periodic bottom-line losses point to structural cost, pricing, or non-recurring charge issues that can erode reinvestment capacity, impair margin stability, and complicate multi-quarter planning.
Rising Debt LoadMaterial debt increases raise financial risk, especially given earnings inconsistency. Higher leverage increases interest burdens and tightens liquidity cushions, limiting flexibility for R&D, capex or M&A, and making the firm more sensitive to cash-flow setbacks over the medium term.
Inconsistent Returns On EquityRecurrent negative ROE episodes signal difficulty converting equity into sustainable profits. This reflects uneven capital efficiency and raises questions about long-term allocation decisions, as inconsistent ROE can deter reinvestment efficacy and constrain shareholder value creation.
Piramal Pharma Limited News
PPLPHARMA FAQ
What was Piramal Pharma Limited’s price range in the past 12 months?
Piramal Pharma Limited lowest stock price was ₹132.50 and its highest was ₹217.75 in the past 12 months.
What is Piramal Pharma Limited’s market cap?
Piramal Pharma Limited’s market cap is ₹239.04B.
When is Piramal Pharma Limited’s upcoming earnings report date?
Piramal Pharma Limited’s upcoming earnings report date is Aug 05, 2026 which is in 17 days.
How were Piramal Pharma Limited’s earnings last quarter?
Piramal Pharma Limited released its earnings results on Apr 28, 2026. The company reported ₹0.9 earnings per share for the quarter, missing the consensus estimate of ₹0.96 by -₹0.06.
Is Piramal Pharma Limited overvalued?
According to Wall Street analysts Piramal Pharma Limited’s price is currently Overvalued.
Does Piramal Pharma Limited pay dividends?
Piramal Pharma Limited pays a Notavailable dividend of ₹0.14 which represents an annual dividend yield of 0.08%. See more information on Piramal Pharma Limited dividends here
What is Piramal Pharma Limited’s EPS estimate?
Piramal Pharma Limited’s EPS estimate is -0.66.
How many shares outstanding does Piramal Pharma Limited have?
Piramal Pharma Limited has 1,331,348,100 shares outstanding.
What happened to Piramal Pharma Limited’s price movement after its last earnings report?
Piramal Pharma Limited reported an EPS of ₹0.9 in its last earnings report, missing expectations of ₹0.96. Following the earnings report the stock price went down -2.637%.
Which hedge fund is a major shareholder of Piramal Pharma Limited?
Currently, no hedge funds are holding shares in IN:PPLPHARMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Piramal Pharma Limited
Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities and distribution network. It also operates contract development and manufacturing organization that provides services across the drug life cycle, including discovery, development, and commercial manufacturing of drug substances and products; offers inhalation anesthetics, intrathecal therapy, injectable pain and anesthesia drugs, and other generic and specialty products; and analgesics, skin care, vitamin/mineral supplement, kids’ wellness, digestives, women’s health, and hygiene, as well as adult incontinence. The company was incorporated in 2020 and is based in Mumbai, India.
Technical Analysis
Biocon Limited
―
Concord Biotech Ltd.
―
Dishman Carbogen Amcis Ltd.
―
Jubilant Ingrevia Ltd.
―
Syngene International Ltd.
―